Nadar SK - Search Results

1

Managing hypertension during the COVID-19 pandemic.

Nadar SK, Tayebjee MH, Stowasser M, Byrd JB. Nadar SK, et al. J Hum Hypertens. 2020 Jun;34(6):415-417. doi: 10.1038/s41371-020-0356-y. Epub 2020 May 14. J Hum Hypertens. 2020. PMID: 32409727 Free PMC article. No abstract available.

2

Ventricular interdependence in hypertension: fact or fiction?

Elsisi IFHA, Tan FSC, Nadar SK, Tayebjee MH. Elsisi IFHA, et al. Among authors: nadar sk. J Hum Hypertens. 2019 Jul;33(7):489-490. doi: 10.1038/s41371-019-0202-2. Epub 2019 Apr 16. J Hum Hypertens. 2019. PMID: 30992513 No abstract available.

3

New guidelines with few takers: will the new American guidelines ever be accepted?

Nadar SK, Stowasser M. Nadar SK, et al. J Hum Hypertens. 2018 Jun;32(6):387-389. doi: 10.1038/s41371-018-0049-y. Epub 2018 Mar 1. J Hum Hypertens. 2018. PMID: 29497151 No abstract available.

4

Strengthening a societal tie and other new initiatives for 2019.

Stowasser M, Nadar SK, Byrd JB. Stowasser M, et al. Among authors: nadar sk. J Hum Hypertens. 2019 Mar;33(3):173. doi: 10.1038/s41371-019-0172-4. Epub 2019 Mar 7. J Hum Hypertens. 2019. PMID: 30846845 No abstract available.

5

Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.

Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY. Tayebjee MH, et al. Among authors: nadar sk. Am J Hypertens. 2005 Mar;18(3):325-9. doi: 10.1016/j.amjhyper.2004.09.014. Am J Hypertens. 2005. PMID: 15797648

6

Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension: relationship to indices of angiogenesis.

Patel JV, Lim HS, Nadar S, Tayebjee M, Hughes EA, Lip GY. Patel JV, et al. J Hypertens. 2006 Jan;24(1):117-21. doi: 10.1097/01.hjh.0000198034.09010.bc. J Hypertens. 2006. PMID: 16331109

7

Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.

Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tayebjee MH, et al. Among authors: nadar sk. Am J Hypertens. 2004 Sep;17(9):770-4. doi: 10.1016/j.amjhyper.2004.06.023. Am J Hypertens. 2004. PMID: 15363818

8

Inflammation and hypertension: more evidence but is there anything new?

Nadar SK, Goyal D. Nadar SK, et al. J Hum Hypertens. 2021 Jul;35(7):561-563. doi: 10.1038/s41371-020-00463-7. Epub 2020 Dec 7. J Hum Hypertens. 2021. PMID: 33288857 No abstract available.

9

Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Tayebjee MH, et al. Am J Hypertens. 2004 Sep;17(9):764-9. doi: 10.1016/j.amjhyper.2004.05.019. Am J Hypertens. 2004. PMID: 15363817 Clinical Trial.

10

The heart in hypertension.

Nadar SK, Lip GYH. Nadar SK, et al. J Hum Hypertens. 2021 May;35(5):383-386. doi: 10.1038/s41371-020-00427-x. Epub 2020 Oct 12. J Hum Hypertens. 2021. PMID: 33046827 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters